Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, up previously from $11.00.
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Candel Therapeutics Announces Pricing of Public Offering
Candel Therapeutics Announces $80 Million Proposed Public Offering
Candel Therapeutics stock up 172% after Phase III prostate cancer success [Yahoo! Finance]